Location: Cleveland Clinic Main Campus
Dr. Labhasetwar laboratory’s primary research focus over the past 25+ years has been in both basic and translational nanomedicine, with specific interest in cancer imaging and therapy (metastasis, drug resistance), cardiovascular diseases (restenosis, cardiac arrhythmia), and neuroprotective treatments for CNS injuries (stroke, spinal cord and blast-associated traumatic brain injury).
Professor, Cleveland Clinic Lerner College of Medicine
Staff, Dept. of Biomedical Engineering, Lerner Research Institute and Taussig Cancer Institute
Director, Cancer Nanomedicine Program
Our laboratory's research focus is on exploring unique attributes of nanotechnology to find effective therapy for diseases that are difficult to treat, or for which there is no treatment. We investigate, design, develop, and evaluate potential new "nanomedicines," with the ultimate objective of translating our research from bench to bedside.
In our current research projects, we aim to: (a) understand the role of epigenetic changes in tumor drug resistance and metastasis and create nanotherapeutics to treat both primary and metastatic tumors; (b) explore effective therapies for stroke, particularly methods of preventing reperfusion injury and facilitating neurological repair mechanisms; (c) investigate novel neuroprotective and regenerative therapies for spinal cord injury and blast-associated traumatic brain injury; (d) develop a balloon-based delivery system for treating peripheral artery disease; and (e) find a treatment that can delay photoreceptor degeneration in retinitis pigmentosa.
We are innovative and active in developing new intellectual property, as well as in the patenting, licensing, and commercialization of our technologies to ultimately benefit patients. Our research is funded primarily by the National Institutes of Health and the Department of Defense.
Neuroprotective Nanoparticles for treating CNS injuries: We began investigating the efficacy of unique neuroprotective nanoparticles in CNS injuries, particularly in stroke and spinal cord injury. We recently expanded my research into the area of blast wave-associated traumatic brain injury (bTBI), a significant issue for the military. Our overall therapeutic strategy is to inhibit the progression of the secondary injury cascades of degenerative events that follow the primary injury and promote the endogenous brain-repair mechanisms. Our recent and ongoing studies have demonstrated that delivery of neuroprotective nanoparticles at the time of reperfusion in a stroke model is effective in minimizing the damage due to ischemia/reperfusion injury, leading to neuronal regeneration and functional recovery over time. We are now expanding our research to other types of CNS injuries.
Epigenetic cancer nanotherapy and cancer drug resistance/metastasis: We have been studying nanoparticles for cancer nanomedicine, particularly as a drug-/gene-delivery system to overcome resistance to chemotherapy drugs. Our laboratory’s recent focus has been on understanding the role of epigenetic changes in cancer drug resistance and tumor metastasis. In this regard, we have been investigating epigenetic nanotherapy for treating resistant and metastatic breast tumors. We are also examining the role of epigenetics in breast cancer stem cells and testing the approach of reprogramming them with epigenetic drugs to make them more susceptible to conventional anticancer drugs.
Cellular uptake and intracellular trafficking of nanoparticles: My laboratory has extensively investigated the mechanism of cellular uptake of nanoparticles (NPs) and their intracellular trafficking. We first discovered that poly lactic co-glycolic acid (PLGA) NPs rapidly escape endosomes following their cellular uptake, but in our subsequent studies, we found that only a small fraction of the internalized NPs escape endosomes and are retained by cells. A major fraction (85%) of these internalized NPs remains in recycling endosomes and undergoes exocytosis. This observation led us to further studies to understand the role of NP surface characteristics on cellular uptake, endosomal escape, and retention.
Role of biophysics of membrane lipids in drug delivery: We found that biophysical interactions of nanoparticles (NPs) depend on both biophysical (e.g., membrane fluidity) properties of membrane lipids and NP characteristics (interfacial properties). Recently, we determined that biomechanics (bending force) and thermodynamics (“Gibbs free energy”) of interactions of NPs with cell membrane lipids play an important role in endocytosis and escape of NPs from endosomes. We also found that selective biophysical interaction of NPs with the membrane lipids of cancer cells vs. normal cells could be developed as a new targeting approach for drug/gene delivery.
View publications for Vinod Labhasetwar, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Proulx J, Joshi C, Vijayaraghavalu S, Saraswathy M, Labhasetwar V, Ghorpade A, Borgmann K. Arginine-Modified Polymers Facilitate Poly (Lactide-Co-Glycolide)-Based Nanoparticle Gene Delivery to Primary Human Astrocytes. Int J Nanomedicine. 2020 May 22;15:3639-3647. doi: 10.2147/IJN.S250865. PMID: 32547019; PMCID: PMC7250304.
Vijayaraghavalu S, Gao Y, Rahman MT, Rozica R, Sharifi N, Midura RJ, Labhasetwar V. Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials, 227, 2020, 119558. https://doi.org/10.1016/j.biomaterials.2019.119558
Andrabi SS, Yang J, Gao Y, Kuang Y, Labhasetwar V. Nanoparticles with antioxidant enzymes protect injured spinal cord from neuronal cell apoptosis by attenuating mitochondrial dysfunction. J Control Release, 317, 2020, 300-311. https://www.ncbi.nlm.nih.gov/pubmed/31805339
S. Vijayaraghavalu, Y. Gao, M. T. Rahman, R. Rozic, N. Sharifi, R. J. Midura, V. Labhasetwar, Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials 227, 119558 2020. Picked as the Editor’s Choice Article in Science Translational Medicine 27 Nov 2019: Vol. 11, Issue 520, eaaz9759 DOI: 10.1126/ https://stm.sciencemag.org/content/11/520/eaaz9759.full
Lu S, Morris VB, Labhasetwar V. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells. J Pharmacol Exp Ther. 370(3), 2019, 902-910. https://www.ncbi.nlm.nih.gov/pubmed/30940690
Vijayaraghavalu S, Labhasetwar V. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. Drug Deliv Transl Res. 8, 2018 1289-1299. doi: 10.1007/s13346-018-0556-y.
Balog BM, Deng K, Labhasetwar V, Jones KJ, Damaser MS. Electrical stimulation for neuroregeneration in urology: a new therapeutic paradigm. Curr Opin Urol. 2019 Jul;29(4):458-465.
Lu S, Morris VB, Labhasetwar V. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells. J Pharmacol Exp Ther. 2019 Sep;370(3):902-910.
Gao Y, Vijayaraghavalu S, Stees M, Kwon BK, Labhasetwar V. Evaluating accessibility of intravenously administered nanoparticles at the lesion site in rat and pig contusion models of spinal cord injury. J Control Release. 2019 May 28;302:160-168.
Joshi CR, Raghavan V, Vijayaraghavalu S, Gao Y, Saraswathy M, Labhasetwar V, Ghorpade A. Reaching for the Stars in the Brain: Polymer-Mediated Gene Delivery to Human Astrocytes. Mol Ther Nucleic Acids. 2018 Sep 7;12:645-657.
Vijayaraghavalu S, Labhasetwar V. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. Drug Deliv Transl Res. 2018 Oct;8(5):1289-1299.
Hammiller B, Karuturi BVK, Miller C, Holmes M, Labhasetwar V, Madsen G, Hansen LA. Delivery of antioxidant enzymes for prevention of ultraviolet irradiation-induced epidermal damage. J Dermatol Sci. 2017 Dec;88(3):373-375.
Kim MS, Stees M, Karuturi BVK, Vijayaraghavalu S, Peterson RE, Madsen GL, Labhasetwar V. Pro-NP™ protect against TiO2 nanoparticle-induced phototoxicity in zebrafish model: exploring potential application for skin care. Drug Deliv Transl Res. 2017 Jun;7(3):372-382.
Joshi CR, Labhasetwar V, Ghorpade A. Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery. J Neuroimmune Pharmacol. 2017 Mar;12(1):51-83.
Adjei IM, Sharma B, Peetla C, Labhasetwar V. Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer. J Control Release. 2016 Jun 28;232:83-92.
Petro M, Jaffer H, Yang J, Kabu S, Morris VB, Labhasetwar V. Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. Biomaterials. 2016 Mar;81:169-180.
Raghavan V, Vijayaraghavalu S, Peetla C, Yamada M, Morisada M, Labhasetwar V. Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids. Langmuir. 2015 Oct 27;31(42):11564-73.
Kabu S, Gao Y, Kwon BK, Labhasetwar V. Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury. J Control Release. 2015 Dec 10;219:141-154
Kabu S, Jaffer H, Petro M, Dudzinski D, Stewart D, Courtney A, Courtney M, Labhasetwar V. Blast-Associated Shock Waves Result in Increased Brain Vascular Leakage and Elevated ROS Levels in a Rat Model of Traumatic Brain Injury. PLoS One. 2015 May 29;10(5):e0127971
Morris VB, Labhasetwar V. Arginine-rich polyplexes for gene delivery to neuronal cells. Biomaterials. 2015 Aug;60:151-60
Snow-Lisy DC, Sabanegh ES Jr, Samplaski MK, Labhasetwar V. Anatomical Targeting Improves Delivery of Unconjugated Nanoparticles to the Testicle. J Urol. 2015 Oct;194(4):1155-61.
Labhasetwar V. The impact of 'negative data'. Drug Deliv Transl Res. 2015 Feb;5(1):1-2
Cramer SA, Adjei IM, Labhasetwar V. Advancements in the delivery of epigenetic drugs. Expert Opin Drug Deliv. 2015;12(9):1501-12.
Lu S, Morris VB, Labhasetwar V. Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes. Mol Pharm. 2015 Feb 2;12(2):621-9
Labhasetwar V. Biophysics of cell membrane and nanoparticle interface: Original research article: Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, 2002. J Control Release. 2014 Sep 28;190:50-2.
Peetla C, Jin S, Weimer J, Elegbede A, Labhasetwar V. Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape. Langmuir. 2014 Jul 1;30(25):7522-32
Adjei IM, Sharma B, Labhasetwar V. Nanoparticles: cellular uptake and cytotoxicity. Adv Exp Med Biol. 2014;811:73-91.
Snow-Lisy DC, Sabanegh ES Jr, Samplaski MK, Morris VB, Labhasetwar V. Superoxide dismutase-loaded biodegradable nanoparticles targeted with a follicle-stimulating hormone peptide protect Sertoli cells from oxidative stress. Fertil Steril. 2014 Feb;101(2):560-7.
Brede C, Labhasetwar V. Applications of nanoparticles in the detection and treatment of kidney diseases. Adv Chronic Kidney Dis. 2013 Nov;20(6):454-65.
Jaffer H, Adjei IM, Labhasetwar V. Optical imaging to map blood-brain barrier leakage. Sci Rep. 2013 Nov 1;3:3117.
Peetla C, Vijayaraghavalu S, Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev. 2013 Nov;65(13-14):1686-98
Adjei IM, Peetla C, Labhasetwar V. Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine (Lond). 2014 Feb;9(2):267-78.
Lu S, Labhasetwar V. Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA. Drug Deliv Transl Res. 2013 Apr 1;3(2):183-94.
Sharma B, Peetla C, Adjei IM, Labhasetwar V. Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett. 2013 Jul 1;334(2):228-36
Vijayaraghavalu S, Labhasetwar V. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion. Cancer Lett. 2013 Apr 30;331(1):122-9.
Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm. 2013 Jan 7;10(1):337-52
Vijayaraghavalu S, Peetla C, Lu S, Labhasetwar V. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol Pharm. 2012 Sep 4;9(9):2730-42
Jaffer H, Morris VB, Stewart D, Labhasetwar V. Advances in stroke therapy. Drug Deliv Transl Res. 2011 Dec 1;1(6):409-19
Labhasetwar V. Drug resistance in cancer therapy. Drug Deliv Transl Res. 2011 Dec;1(6):407-8.
Foy SP, Labhasetwar V. Oh the irony: Iron as a cancer cause or cure? Biomaterials. 2011 Dec;32(35):9155-8.
Snow-Lisy DC, Samplaski MK, Labhasetwar V, Sabanegh ES Jr. Drug delivery to the testis: current status and potential pathways for the development of novel therapeutics. Drug Deliv Transl Res. 2011 Oct;1(5):351-60
Labhasetwar V. Neurodegenerative diseases: challenges. Drug Deliv Transl Res. 2011 Oct;1(5):349-50.
Labhasetwar V, Egashira K, Hanes J. Editorial. Drug Deliv Transl Res. 2011 Feb;1(1):1.
Sharma B, Ma W, Adjei IM, Panyam J, Dimitrijevic S, Labhasetwar V. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res. 2011 Feb;1(1):43-52.
Borgmann K, Rao KS, Labhasetwar V, Ghorpade A. Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses. 2011 Aug;27(8):853-62.
Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E, Labhasetwar V. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm. 2010 Dec 6;7(6):2334-48.
Manthe RL, Foy SP, Krishnamurthy N, Sharma B, Labhasetwar V. Tumor ablation and nanotechnology. Mol Pharm. 2010 Dec 6;7(6):1880-98.
Yallapu MM, Foy SP, Jain TK, Labhasetwar V. PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications. Pharm Res. 2010 Nov;27(11):2283-95
Foy SP, Manthe RL, Foy ST, Dimitrijevic S, Krishnamurthy N, Labhasetwar V. Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors.ACS Nano. 2010 Sep 28;4(9):5217-24.
Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv. 2008 Dec;1(3):209-16.
Labhasetwar V, Zborowski M, Abramson AR, Basilion JP. Nanoparticles for imaging, diagnosis, and therapeutics. Mol Pharm. 2009 Sep-Oct;6(5):1261-2.
Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials. 2009 Dec;30(35):6748-56.
Rao KS, Ghorpade A, Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv. 2009 Aug;6(8):771-84.
Peetla C, Stine A, Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol Pharm. 2009 Sep-Oct;6(5):1264-76.
Jin S, Labhasetwar V. Nanotechnology in urology. Urol Clin North Am. 2009 May;36(2):179-88
Peetla C, Rao KS, Labhasetwar V. Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm. 2009 Sep-Oct;6(5):1311-20.
Peetla C, Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir. 2009 Feb 17;25(4):2369-77.
Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009 May;23(5):1384-95.
Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008 Nov;29(33):4429-38.
Vasir JK, Labhasetwar V. Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials. 2008 Nov;29(31):4244-52.
Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK, Labhasetwar V. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm. 2008 Sep-Oct;5(5):849-62
Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials. 2008 Oct;29(29):4012-21
Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol. 2008 Dec;151(2-3):565-77.
Peetla C, Labhasetwar V. Biophysical characterization of nanoparticle-endothelial model cell membrane interactions. Mol Pharm. 2008 May-Jun;5(3):418-29.
Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008 Mar-Apr;5(2):316-27.
Vasir JK, Labhasetwar V. Preparation of biodegradable nanoparticles and their use in transfection. CSH Protoc. 2008 Jan 1;2008:pdb.prot4888.
Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V. Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):237-47.
Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007 Aug 10;59(8):718-28.
Vijayaraghavalu S, Raghavan D, Labhasetwar V. Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr Opin Investig Drugs. 2007 Jun;8(6):477-84.
Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv. 2006 May;3(3):325-44.
Panyam J, Labhasetwar V. Targeting intracellular targets. Curr Drug Deliv. 2004 Jul;1(3):235-47.
Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr Opin Biotechnol. 2005 Dec;16(6):674-80
Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005 Sep-Oct;2(5):373-83.
Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005 Aug;4(4):363-74.
Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm. 2004 May-Jun;1(3):211-9.
Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005 May-Jun;2(3):194-205.
Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm. 2004 Jan 12;1(1):77-84.
Sahoo SK, Panda AK, Labhasetwar V. Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells. Biomacromolecules. 2005 Mar-Apr;6(2):1132-9.
Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004 Nov 1;112(2):335-40.
Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci. 2004 Jul;93(7):1804-14.
Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004 Apr;21(4):641-8.
Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004 May;24(3):294-301.
Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res. 2004 Feb;21(2):354-64.
Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003 Dec 15;8(24):1112-20.
Qaddoumi MG, Gukasyan HJ, Davda J, Labhasetwar V, Kim KJ, Lee VH. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol Vis. 2003 Oct 15;9:559-68.
Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003 Sep 19;92(1-2):173-87.
Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003 Aug 27;262(1-2):1-11.
Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003 Feb;20(2):212-20.
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47.
Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002 Sep 5;244(1-2):105-15.
Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002 Aug;16(10):1217-26.
Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002 Jul 18;82(1):105-14.
Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 2002 Feb 21;233(1-2):51-9.
|US Patent||Patent Title||Issue Date||First-Named Inventor|
|10,517,934||Compositions and methods for the treatment of photoaging and other conditions||12/31/2019||Vinod Labhasetwar, PhD|
|10,226,885||Nanogel-mediated drug delivery||02/19/2019||Vinod Labhasetwar, PhD|
|10,016,488||Nitric oxide synthase nanoparticles for treatment of vascular disease||07/10/2018||Vinod Labhasetwar, PhD|
|9,138,416||Sustained-release nanoparticle compositions and methods of using the same||09/22/2015||Vinod Labhasetwar, PhD|
|8,865,216||Surface-modified nanoparticles for intracellular delivery of therapeutic agents and compositions for making same||10/21/2014||Vinod Labhasetwar, PhD|
|8,507,437||Apoptosis-modulating p53 protein therapy for vascular disorders and nanoparticles containing the same||08/13/2013||Vinod Labhasetwar, PhD|
|8,182,807||Method for inhibiting reperfusion injury in the brain||05/22/2012||Vinod Labhasetwar, PhD|
|7,727,554||Sustained-release nanoparticle compositions and methods for using the same||06/01/2010||Vinod Labhasetwar, PhD|
|7,332,159||Method and composition for inhibiting reperfusion injury in the brain||02/19/2008||Vinod Labhasetwar, PhD|
|6,814,980||Microspheres containing condensed polyanionic bioactive agents and methods for their production||11/09/2004||Vinod Labhasetwar, PhD|
|6,395,253||Microspheres containing condensed polyanionic bioactive agents and methods for their production||05/28/2002||Vinod Labhasetwar, PhD|
|6,143,037||Compositions and methods for coating medical devices||11/07/2000||Vinod Labhasetwar, PhD|
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.Learn More
With this new support, Dr. Labhasetwar will test the ability of a novel dual-action agent, which combines a tissue plasminogen activator with an antioxidant-loaded nanoparticle, to dissolve blood clots and protect the brain from reperfusion injury following stroke.
Dr. Labhasetwar engineered a sustained-release biodegradable nanoparticle loaded with the cancer drug docetaxel and found that in a preclinical model of prostate cancer it effectively halted cancer metastasis in the bone when administered with a monoclonal antibody.